Substituted tetrahydropyrrolo[1,2-a]pyrazines as alpha v integrin inhibitors
US11292802B2 · kind B2 · utility
0Cited by
3References
16Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 5, 2018 |
| Grant date | Apr 5, 2022 |
| Priority date | — |
| Expiry date | Feb 26, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D487/04
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
The disclosure relates to compounds of formula I: Formula I which inhibit αV-containing integrins, and includes pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of αV-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.